TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27533976

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4547

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4547
Study: 24057101

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg intravenous before anesthesia)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 110
Study: 22101698

Group type: EXPERIMENTAL
Intervention: ELP (Bo-gu Ling)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 19258378

Group type: EXPERIMENTAL
Intervention: Training GPs
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cortisone
Number of subjects: 200
Study: 17695602

Group type: EXPERIMENTAL
Intervention: Dyract Flow
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Admira Flow
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Filtek Flow
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Filtek Z250
Number of subjects: 37

Group type: COMPARATOR
Intervention: All materials tested
Number of subjects: 37
Study: 15223498

Group type: EXPERIMENTAL
Intervention: Initial healing rates calculated by method 1
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Initial healing rates calculated by method 2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Negative initial healing rates
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Initial healing rates (both methods)
Number of subjects: 17
Study: 11317194

Group type: EXPERIMENTAL
Intervention: COER-verapamil (180-540 mg at bedtime)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: COER-verapamil
Number of subjects: 281
Study: 9496925

Group type: EXPERIMENTAL
Intervention: Experimental gum (2.5% alpha-tricalcium-phosphate)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control gum
Number of subjects: 14
Study: 7805631

Group type: EXPERIMENTAL
Intervention: Behavioral family-based treatment targeting parents and children for weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle or aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontargeted controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calisthenics control
Number of subjects: 0
Study: 3362176

Group type: EXPERIMENTAL
Intervention: High-stearic-acid diet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-oleic-acid diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-palmitic-acid diet
Number of subjects: 11
Study: 30555165

Group type: EXPERIMENTAL
Intervention: Glasdegib plus low-dose cytarabine (LDAC)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDAC) alone
Number of subjects: 132
Study: 29081267

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (≥60 seconds after delivery)
Number of subjects: 1566

Group type: COMPARATOR
Intervention: Immediate cord clamping (≤10 seconds after delivery)
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Number of subjects: 1566

Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 1566
Study: 26160319

Group type: EXPERIMENTAL
Intervention: Sevoflurane-fentanyl anaesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous midazolam-fentanyl anaesthesia (Control)
Number of subjects: 80
Study: 23173759

Group type: EXPERIMENTAL
Intervention: Complex intervention including patient interview about rehabilitation, comprehensive information to GP about individual needs, encouragement for GP to contact patient proactively
Number of subjects: 955

Group type: COMPARATOR
Intervention: Control group (usual procedures)
Number of subjects: 955
Study: 21821568

Group type: EXPERIMENTAL
Intervention: Performance-based subsidies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (facilities not financed by performance-based subsidies)
Number of subjects: 0
Study: 19081414

Group type: EXPERIMENTAL
Intervention: Transradial PCI with maximal antiplatelet therapy (clopidogrel and abciximab)
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Patients with major bleeding
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 1348
Study: 16395748

Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 10 mg/kg infliximab
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Infliximab (DBT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo (DBT)
Number of subjects: 147
Study: 15537996

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with standard rehabilitation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 32
Study: 10968358

Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 275
Study: 9231892

Group type: EXPERIMENTAL
Intervention: Fixed combination of verapamil slow release (SR) and trandolapril, administered for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1490497

Group type: EXPERIMENTAL
Intervention: Parlodel SRO
Number of subjects: 34

Group type: COMPARATOR
Intervention: Parlodel standard
Number of subjects: 34
Study: 3884766

Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment (prednisone plus azathioprine)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31004493

Group type: EXPERIMENTAL
Intervention: Progressive multi-component (PMC) intervention including lower extremity resistance training at 80% of a 1-repetition maximum, task-specific activities of daily living training, advanced gait and balance training, nutritional supplementation, and nursing support during transition from hospital to home
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (UC) physical therapy
Number of subjects: 200
Study: 30348145

Group type: EXPERIMENTAL
Intervention: GLP-1 RA therapy
Number of subjects: 559
Study: 28002471

Group type: EXPERIMENTAL
Intervention: Omeprazole 2.5 mg/kg/day for neonates born at less than 32 weeks of GA (n = 30)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Omeprazole 1 mg/kg/day for neonates born at more than 32 weeks of GA (n = 24)
Number of subjects: 54
Study: 24438077

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (ET)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Manual toothbrush (MT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Caregiver opinion on ET
Number of subjects: 180
Study: 22158142

Group type: EXPERIMENTAL
Intervention: 8-SET
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 4-SET
Number of subjects: 3

Group type: COMPARATOR
Intervention: 1-SET
Number of subjects: 3
Study: 20675920

Group type: EXPERIMENTAL
Intervention: Regular physical training (highly trained athletes)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 24
Study: 17414239

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Disulfiram and Naltrexone
Number of subjects: 254

Group type: COMPARATOR
Intervention: Disulfiram and Placebo
Number of subjects: 254
Study: 16368032

Group type: EXPERIMENTAL
Intervention: Psychological interventions (cognitive behaviour therapy, counselling)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Psychological intervention (one‐to‐one delivery)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Routine primary care
Number of subjects: 192
Study: 12163777

Group type: EXPERIMENTAL
Intervention: Early hemodynamic optimization (goals: cardiac index >4.5 L x min(‐1) x m(‐2), pulmonary artery occlusion pressure <18 mm Hg, oxygen delivery >600 mL x min(‐1) x m(‐2), oxygen consumption >170 mL x min(‐1) x m(‐2))
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Late hemodynamic optimization (after organ failure)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Normal values as goals or therapy that did not improve oxygen delivery
Number of subjects: 21
Study: 9797239

Group type: EXPERIMENTAL
Intervention: 1% cidofovir gel
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 3% cidofovir gel
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 5% cidofovir gel
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 7705123

Group type: EXPERIMENTAL
Intervention: Mesna (3 mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution (3 mL)
Number of subjects: 20
Study: 2768152

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Methylphenidate (highest dose)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Methylphenidate (lower dose)
Number of subjects: 4
Study: 861124

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitrazepam 2.5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactose (dummy control)
Number of subjects: 20
Study: 31435922

Group type: EXPERIMENTAL
Intervention: Sonoporation (CEUS-IGDD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard chemotherapeutics
Number of subjects: 10
Study: 30942552

Group type: EXPERIMENTAL
Intervention: AEX + TST
Number of subjects: 20

Group type: COMPARATOR
Intervention: TST
Number of subjects: 20
Study: 27613951

Group type: EXPERIMENTAL
Intervention: Tobacco Heating System 2.1 (THS 2.1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combustible Cigarettes (CC)
Number of subjects: 40
Study: 26437502

Group type: EXPERIMENTAL
Intervention: Group A (All Bond 3)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Group B (Clearfil Protect Bond)
Number of subjects: 204
Study: 23541711

Group type: EXPERIMENTAL
Intervention: 3.5 mg Zolpidem Sublingual Tablet (ZST)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 10 mg Immediate-Release (IR) Oral Zolpidem
Number of subjects: 33
Study: 21860242

Group type: EXPERIMENTAL
Intervention: GSE (proanthocyanidin-rich grape seed extract)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSE+F (GSE with fluoride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride (F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 0
Study: 19074594

Group type: EXPERIMENTAL
Intervention: Candesartan (angiotensin II type 1 receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17002566

Group type: EXPERIMENTAL
Intervention: Femoral neck EI to TSM ratio
Number of subjects: 700
Study: 15119520

Group type: EXPERIMENTAL
Intervention: Outpatient strategy using low‐molecular‐weight heparin, dalteparin, administered subcutaneously once daily, adjusted for body weight.
Number of subjects: 131

Group type: COMPARATOR
Intervention: Inpatient strategy using low‐molecular‐weight heparin, dalteparin, administered subcutaneously once daily, adjusted for body weight.
Number of subjects: 131
Study: 10665615

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 600 mg/wk
Number of subjects: 56
Study: 9032651

Group type: EXPERIMENTAL
Intervention: Metacarpophalangeal pattern profile analysis in affected individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with unaffected individuals from the same family
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with people with a different genetic background
Number of subjects: 0
Study: 7984574

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies OKT-4 and OKT-8 used in tuberculous patients
Number of subjects: 174

Group type: COMPARATOR
Intervention: Healthy subjects of different age
Number of subjects: 174
Study: 3549800

Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 3% minoxidil solution
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 30571562

Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide
Number of subjects: 11066

Group type: EXPERIMENTAL
Intervention: Continuation of angiotensin-converting enzyme inhibitor-based therapy
Number of subjects: 11066

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11066
Study: 29587729

Group type: EXPERIMENTAL
Intervention: Axium spinal cord stimulation (SCS) of the dorsal root ganglion (DRG)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 78
Study: 26740197

Group type: EXPERIMENTAL
Intervention: Vaginal prolapse repair with midurethral sling (MUS)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Vaginal prolapse repair without midurethral sling (MUS)
Number of subjects: 231
Study: 25251676

Group type: EXPERIMENTAL
Intervention: ADF-L (lunch)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ADF-D (dinner)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ADF-SM (small meals)
Number of subjects: 74
Study: 22385437

Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency lesioning of the sensory branches of the obturator and femoral nerves
Number of subjects: 18
Study: 21164045

Group type: EXPERIMENTAL
Intervention: Curcumin group (10 participants) ingested 8 g of curcuminoids (C(3)‐Complex) with 16 oz of bottled water.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (5 participants) did not take curcumin.
Number of subjects: 15
Study: 18066139

Group type: EXPERIMENTAL
Intervention: Protein-source tryptophan (deoiled gourd seed) in combination with carbohydrate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Carbohydrate alone
Number of subjects: 7
Study: 15231439

Group type: EXPERIMENTAL
Intervention: Abused/neglected patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Neglect
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 51
Study: 11295690

Group type: EXPERIMENTAL
Intervention: Dipyridamole technetium 99m sestamibi SPECT imaging
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Rest thallium imaging
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (low-dose warfarin sodium and aspirin)
Number of subjects: 203
Study: 9243262

Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam
Number of subjects: 242

Group type: COMPARATOR
Intervention: clindamycin
Number of subjects: 242
Study: 8500309

Group type: EXPERIMENTAL
Intervention: Minimization method of Taves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stratified assignment method
Number of subjects: 0
Study: 3326113

Group type: EXPERIMENTAL
Intervention: Zopiclone 3.75 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29463098

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30
Study: 27064030

Group type: EXPERIMENTAL
Intervention: Drospirenone (DRP)‐containing COCs, combined with metformin (1.5 g/d) and lifestyle modifications
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cyproterone acetate (CPA)‐containing COCs, combined with metformin (1.5 g/d) and lifestyle modifications
Number of subjects: 99
Study: 24637997

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Single-agent chemotherapy alone
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 361
Study: 21824837

Group type: EXPERIMENTAL
Intervention: Real rTMS (20-minute session, 1200 pulses at 100% of individual motor threshold)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 24
Study: 20521348

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (four cycles of carboplatin and paclitaxel)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Presence of mucin
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Presence of p53
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Larger tumor volume
Number of subjects: 250
Study: 17517949

Group type: EXPERIMENTAL
Intervention: pyrimethamine (50 mg/day) plus sulfadiazine (4 g/day) and folinic acid (25 mg/day)
Number of subjects: 3

Group type: COMPARATOR
Intervention: trimethoprim (10 mg/kg/day) plus sulfamethoxazole (50 mg/kg/day) (TMP‐SMX)
Number of subjects: 3
Study: 16826020

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (60-75% of maximal heart rate), 5 days/week for 12 months
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stretching sessions once a week
Number of subjects: 173
Study: 12792513

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (folic acid 5 mg/day; vitamin B(6) 50 mg/day; vitamin B(12) 400 microg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 56
Study: 10676599

Group type: EXPERIMENTAL
Intervention: Intravenous Optison® (FS069) at 0.5 ml
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Intravenous Optison® (FS069) at higher doses (0.2, 3.0, and 5.0 ml)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Adverse event rate with Optison®
Number of subjects: 191
Study: 8800113

Group type: EXPERIMENTAL
Intervention: Continuous infusion of high dose furosemide (mean daily dosage 690 mg, range 250 to 2,000)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bolus injection of high dose furosemide (equal dosage to infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous infusion of high dose furosemide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bolus injection of high dose furosemide
Number of subjects: 20
Study: 1624171

Group type: EXPERIMENTAL
Intervention: High glycine amino acid solution (23% glycine nitrogen)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low glycine amino acid solution (4% glycine nitrogen)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High glycine amino acid solution (25% glycine nitrogen)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low glycine amino acid solution (8% glycine nitrogen)
Number of subjects: 14
Study: 6377884

Group type: EXPERIMENTAL
Intervention: Dialysate at 35.6 degrees C
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dialysate at 36.7 degrees C
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dialysate at 37.8 degrees C
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dialysate cooler than isothermic levels
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dialysate warmer than isothermic levels
Number of subjects: 17
Study: 30654297

Group type: EXPERIMENTAL
Intervention: pembrolizumab + CC-486
Number of subjects: 100

Group type: COMPARATOR
Intervention: pembrolizumab + placebo
Number of subjects: 100
Study: 28560591

Group type: EXPERIMENTAL
Intervention: Individual-level factors (younger age)
Number of subjects: 2968

Group type: EXPERIMENTAL
Intervention: Familial-level factors (living with only one parent or another person while growing up)
Number of subjects: 2968

Group type: EXPERIMENTAL
Intervention: Male gender (among foreign-born youth)
Number of subjects: 2968

Group type: EXPERIMENTAL
Intervention: Parental education level (among Swedish-born youth)
Number of subjects: 2968

Group type: EXPERIMENTAL
Intervention: Condom use
Number of subjects: 2968
Study: 26746436

Group type: EXPERIMENTAL
Intervention: Virtual microscopy adaptive tutorials (VMATs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing resources (e-textbooks and online atlases)
Number of subjects: 0
Study: 24717919

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 257

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 257
Study: 22394464

Group type: EXPERIMENTAL
Intervention: Optimised management based on international guidelines
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual heart failure management by general practitioners
Number of subjects: 80
Study: 19158225

Group type: EXPERIMENTAL
Intervention: DHA oil (7.5 g/d, 3 g DHA/d)
Number of subjects: 34
Study: 17192287

Group type: EXPERIMENTAL
Intervention: Islet transplantation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Type 1 diabetes group
Number of subjects: 15
Study: 12607378

Group type: EXPERIMENTAL
Intervention: Web based IT solutions for studies and registers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central database for randomization and stratification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient direct data reporting into the database
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of web based IT solutions
Number of subjects: 0
Study: 10979879

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (200 mg/wk)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (three times weekly)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 54

Group type: COMPARATOR
Intervention: No training
Number of subjects: 54
Study: 8780431

Group type: EXPERIMENTAL
Intervention: Inositol (18 g/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1467134

Group type: EXPERIMENTAL
Intervention: 20 mg BAY u 3405
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg BAY u 3405
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6382673

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30614769

Group type: EXPERIMENTAL
Intervention: ERAS group (n=100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: CON group (n=100)
Number of subjects: 200
Study: 27814306

Group type: EXPERIMENTAL
Intervention: Treadmill training with Thera-Band for 30 minutes, five times a week for four weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physical therapy for 30 minutes followed by treadmill training only for 30 minutes
Number of subjects: 30
Study: 25294865

Group type: EXPERIMENTAL
Intervention: Leuprolide 7.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Leuprolide 3.75 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 60